Magnetic
Resonance -
Technology
Information
Portal |
Welcome to MRI Technology• |
|
|
| Info Sheets |
| | | | | | | | | | | | | | | | | | | | | | | | |
| Out- side |
| | | | |
|
| | | | |
Result : Searchterm 'Gadoversetamide' found in 1 term [] and 2 definitions []
| 1 - 3 (of 3) Result Pages : [1] | | | | Searchterm 'Gadoversetamide' was also found in the following service: | | | | |
| | |
Gadoversetamide | |
| |
|
Short name: Gd-DTPA-BMEA, generic name: Gadoversetamide
A paramagnetic extracellular MRI contrast agent with positive enhancement. When placed in a magnetic field, gadoversetamide decreases T1 and T2 relaxation times in tissues where it accumulates. At the recommended dose, the effect is primarily on T1
relaxation time, and produces an increase in signal intensity (brightness). See Contrast Agents and OptiMARK™. | | | | | • Share the entry 'Gadoversetamide': | | | • View the NEWS results for 'Gadoversetamide' (1).
| | | | Further Reading: | | Basics:
|
|
News & More:
| |
| |
| | | | | |
| |
|
OptiMARK® is a formulation of a nonionic gadolinium chelate of diethylenetriamine pentaacetic acid bismethoxyethylamide ( gadoversetamide), for use as a paramagnetic MRI contrast agent.
OptiMARK® ( gadoversetamide injection) is to be administered by intravenous injection.
OptiMARK® is indicated for MRI diagnostic procedures to provide increased enhancement and visualization of lesions of the brain, spine and liver, including tumors. WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m 2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.
Drug Information and Specification T1, Predominantly positive enhancement PHARMACOKINETIC Intravascular, extracellular DOSAGE 0.1 mmol/kg / 0.2 mL/kg PREPARATION Finished product INDICATION Neuro/whole body PRESENTATION Vials of 5, 10, 15, 20, 50 mL and
Pre-filled syringes of 10, 15, 20 and 30 mL DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information TERRITORY TRADE NAME DEVELOPMENT STAGE DISTRIBUTOR Australia OptiMARK® for sale | | | | • View the DATABASE results for 'OptiMARK®' (5).
| | | | Further Reading: | Basics:
|
|
News & More:
| |
| |
| | | | | |
| |
|
Radiographic low-osmolar nonionic contrast agents have less side effects and fewer nephrotoxicity than ionic, high-osmolar agents. Gadolinium-based MRI contrast agents have a different formulation from iodinated X-ray contrast media, and there is no known cross sensitivity between these two types of contrast agents. Intravenous MRI contrast agents, specifically the gadolinium chelates have a high safety and lack of nephrotoxicity compared with X-ray contrast media.
The used gadolinium chelates differ in following properties: linear (e.g., gadodiamide and gadoversetamide have nonionic linear structures) vs. macrocyclic cores, and ionic vs. nonionic types. The nonionic molecules have lower osmolality and viscosity, which increase digestibility at greater concentrations, and make faster bolus injections conceivable.
The macrocyclic molecules (e.g., gadoteridol has a nonionic macrocyclic ring structure) are more stable and show fewer tendencies to dissociate free Gd.
See also ProHance®, Omniscan®, OptiMARK®, Ionic Intravenous Contrast Agents.
See also the related poll result: ' MRI will have replaced 50% of x-ray exams by' | | | | • View the DATABASE results for 'Nonionic Intravenous Contrast Agents' (4).
| | | | Further Reading: | News & More:
|
|
| |
| | | Searchterm 'Gadoversetamide' was also found in the following service: | | | | |
| |
| | 1 - 3 (of 3) Result Pages : [1] |
| |
|
| |
| Look Ups |
| |
|
MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies. | | [last update: 2024-02-26 03:41:00] |
|
|